2026-04-29T07:35:53Zhttps://repisalud.isciii.es/rest/oai/request

oai:repisalud.isciii.es:20.500.12105/229032024-11-29T04:47:11Zcom_20.500.12105_15322com_20.500.12105_2051col_20.500.12105_16967col_20.500.12105_16982col_20.500.12105_16972

00925njm 22002777a 4500 dc Raggi, Paolo author Bellasi, Antonio author Sinha, Smeeta author Bover, Jordi author Rodriguez, Mariano author Ketteler, Markus author Bushinsky, David A author Garg, Rekha author Perello, Joan author Gold, Alex author Chertow, Glenn M author 2020-12 Introduction: Coronary artery calcium (CAC) is highly prevalent and linked with poor outcomes in patients receiving maintenance hemodialysis, and its reduction may improve patient prognosis. SNF472, a selective inhibitor of hydroxyapatite crystallization, slows CAC progression in patients receiving maintenance hemodialysis. In this analysis, we assessed the efficacy of SNF472 in prespecified patient subgroups. Methods: In a randomized clinical trial SNF472 300 mg, SNF472 600 mg, or placebo were infused thrice weekly in 91, 92, and 91 patients receiving maintenance hemodialysis and with CAC at baseline, respectively. In prespecified subanalyses, the percent change in CAC volume score (CACvs) from baseline to week 52 in modified intention-to-treat (mITT) and per-protocol (PP) populations was calculated in the following subgroups: age, sex, diabetes mellitus, dialysis vintage, prior atherosclerotic cardiovascular disease, baseline use of non-calcium and calcium-based phosphate binders, calcimimetics, activated vitamin D, warfarin, and statins. Results: In the main trial, SNF472 significantly reduced CACvs progression compared with placebo (11% versus 20% mITT analyses; P 1/4 0.016; 8% vs. 24% PP analyses; P < 0.001). Treatment differences for CACvs progression were similar across all subgroups, and all interaction Pvalues were non-significant in mITT and PP analyses. Conclusions: SNF472 treatment for 52 weeks reduced CACvs progression compared with placebo in a broad range of patients receiving maintenance hemodialysis. Future studies will determine the impact of SNF472 on cardiovascular events in this population. Raggi P, Bellasi A, Sinha S, Bover J, Rodriguez M, Ketteler M, et al. Effects of SNF472, a Novel Inhibitor of Hydroxyapatite Crystallization in Patients Receiving Hemodialysis - Subgroup Analyses of the CALIPSO Trial. Kidney Int Rep. 2020 Dec;5(12):2178-82. 2468-0249 https://hdl.handle.net/20.500.13003/19563 https://hdl.handle.net/20.500.12105/22903 33305110 10.1016/j.ekir.2020.09.032 Kidney International Reports 2-s2.0-85097110742 596812300044 L2010065834 Coronary calcification Vascular calcification Hemodialysis Effects of SNF472, a Novel Inhibitor of Hydroxyapatite Crystallization in Patients Receiving Hemodialysis - Subgroup Analyses of the CALIPSO Trial